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atent Foramen Ovale:
losing Arguments*
ark Reisman, MD
eattle, Washington
he unsettling diagnosis of “cryptogenic” stroke presents
oth patient and physician with a variety of potential
athophysiologic culprits of uncertain clinical significance.
uring the last decade patent foramen ovale (PFO), previ-
usly considered to be a highly prevalent but benign
ongenital anomaly is more frequently insinuated into the
ifferential diagnosis of stroke/transient ischemic attack
TIA). Despite the fact that at the time of the index event
here are often “no witnesses” or identifiable accomplices
e.g., deep vein thrombosis, intratunnel clot), there is
merging circumstantial evidence that implicates a PFO.
he conundrum we face is knowing who should receive a
eptal closure device and who should be treated medically.
etrospective PFO closure studies have demonstrated high
rocedural success, low complications, and favorable long-
erm outcomes. However, controversy remains in the ab-
ence of randomized clinical data as to the optimal man-
gement of these often young, active, and otherwise healthy
atients, who are disabled from a stroke or have had a TIA
nd fear a subsequent event.
See page 404
In this issue of JACC: Cardiovascular Interventions, Ford
t al. (1) identified the PFO as the culprit, after other
otential sources of TIA or stroke were ruled out. Thus, a
iagnosis of exclusion was used for clinical decision-making
nd definitive treatment with a closure device. The study
howed a low incidence of major complications, an excellent
losure rate adjudicated by transthoracic echocardiogram
TTE) and a very low recurrence rate of stroke or TIA
2.8% at 4 years). Recurrence of stroke/TIA was signifi-
antly higher in those with elevated pulmonary artery
ressure (hazard ratio [HR]: 1.12, p 0.009), elevated right
entricular pressure (HR: 1.09, p  0.04), factor V Leiden
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
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From the Swedish Heart and Vascular Institute, Seattle, Washington.utation (HR: 7.42, p  0.014), and protein S deficiency
HR: 12.2, p  0.002). In this area of clinical uncertainty,
hould these results be used to guide therapy and should
FO closure be considered the standard of care?
The demographic data are similar to other reports of
FO closure, with patients younger than traditionally seen
n stroke populations (mean age 53.4 years) and an absence
f a clearly identifiable cause (2–4). The relatively low
ercentage of patients that underwent carotid ultrasound
25%) and Holter monitor evaluation (36%) was somewhat
urprising. Additional information would have been helpful
o thoroughly evaluate the mechanistic role of the PFO,
uch as lower extremity venous duplex (5) and travel history
ithin the weeks preceding the event. (6). Furthermore,
nowledge of the presence or absence of migraine headaches
7) would have enhanced the evaluation, since migraine has
een associated with a high incidence of venous thrombosis
8) as well as PFO and stroke.
The decision to proceed with PFO closure in this study
epended only on the clinical presentation and the presence
f the PFO defect. Right to left shunts were confirmed on
he basis of TTE and transesophageal echocardiography
TEE) in all patients: 17% had a severe shunt, 45% had a
oderate shunt, and 36% had a minimal shunt. The ability
o predict stroke/TIA on the basis of shunt size remains
ontroversial (9–11). More importantly, the determination
f the magnitude of the shunt varies significantly depending
n the method of detection. Among the available modali-
ies, Power M-mode transcranial Doppler is the most
ensitive, followed by TEE, and TTE is the least sensitive
12). Intravascular volume status, location of venous injec-
ion of agitated saline (upper vs. lower extremity), and the
bility to perform an adequate Valsalva maneuver plays a
ignificant role in detection and reproducibility. Further-
ore, differentiating PFO diameter size from right to left
hunt magnitude can be valuable, because our group ob-
erved that small anatomical PFOs can conduct a dispro-
ortionally high volume across the atrial septum (12).
It is critical to recognize that all PFOs are not created
qual. The image of a small probe patent PFO seen in
urgical texts rarely resembles the morphology of PFOs we
bserved in patients referred for PFO closure evaluation.
or example, PFOs with coexisting atrial septal aneurysms
epresent an important morphological feature. Although a
isnomer, these often extremely redundant septum pri-
ums have large excursions between atria, can be associated
ith long or short tunnels (overlap between septum secun-
um and primum), and have been linked in several studies
ith a high risk of recurrent stroke in medically treated
atients (13–15). Atrial septal aneurysm was present in 23%
f the sample in the Ford et al. (1) study, which is consistent
ith other reports (2,16). The prevalence of structures suchs Chiari’s network, a congenital remnant of the right valve
o
c
a
t
o
s
(
p
f
b
s
T
r
T
t
c
s
e
i
d
t
r
s
e
h
b
h
p
c
c
f
b
a
c
l
o
c
b
p
p
i
r
(
o
s
l
r
a
d
e
h
p
w
T
t
i
W
t
r
p
a
o
P
e
t
t
p
t
s
i
c
b
t
R
r
I
E
R
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 5 , 2 0 0 9 Reisman
MA Y 2 0 0 9 : 4 1 2 – 4 Editorial Comment
413f the sinus venosus, were not reported, but may have
linical significance in increasing stroke risk (17).
After PFO closure, the presence of a residual shunt seen
t a median follow-up of 129 days was 4.3%. This is lower
han seen in many reports and might reflect the insensitivity
f TTE (2,18). Transthoracic echocardiography has been
hown to be one-half as sensitive as TEE in shunt detection
12). Another explanation might be the use of the Am-
latzer septal occluder. Using the Amplatzer septal occluder
or PFO closure might at first glance be counterintuitive,
ecause it is designed for treatment of a hole in the atrial
eptum (atrial septal defect) and not a flap as seen in PFO.
he high closure rate demonstrated in this study may be a
esult of the central disc of the device plugging the tunnel.
hus, this device might have advantages over PFO devices
hat are designed with left and right “clamshells” with a
onnecting pin that sits within the tunnel. In addition,
ingle time point analysis might be subject to error. In our
xperience we have seen both a reduction as well as an
ncrease in residual shunt in late follow-up (2). These
isparities might be due to the effect of tissue growth over
he device, misalignment (subtle migration), or device
etraction.
Recurrent events occurred in eight patients (2.3%), 7
trokes and 2 TIAs. Following the event, transesophageal
chocardiography was performed in 6 patients, and 1 patient
ad a TTE. There were no findings of intracardiac throm-
us, device dislodgement, or residual shunts. Two patients
ad an event before first follow-up. Of the remaining 6
atients, 5 (83%) were taking warfarin, 3 (50%) were taking
lopidogrel, and 5 (83%) were taking aspirin, after device
losure and before the recurrent neurologic event. There-
ore, they were maximally medically managed. The com-
ined end point of stroke and TIA was 0.9% and 2.8% at 1
nd 4 years, respectively. This recurrence rate is low and
ompares favorably to many of the nonrandomized studies
ooking at medical therapy (19,20). The majority of events
ccurred in the first 2 years after closure, an outcome
onsistent with other studies (21). This result is important,
ecause the recently completed CLOSURE I study com-
aring PFO closure with medical therapy has a primary end
oint of stroke or TIA at the 2-year timeframe. Interest-
ngly, none of the patients with residual shunts had recur-
ent events, which is consistent with the data of Harms et al.
2). One could speculate that, by changing the architecture
f the tunnel and having large baffles on each side of the
eptum, there is a consequential reduction in size and/or
oad of cerebral embolization.
Atrial septal aneurysm did not increase the risk of
ecurrence after device placement. The abatement of the
trial septal aneurysm risk of recurrent stroke by PFO
evices was shown in this trial as in others (2) and is
ncouraging, because atrial septal aneurysm might carry the
ighest risk of primary and repeat neurologic events.Five of the patients with recurrent events had thrombo-
hilia. Factor V Leiden mutation and protein S deficiency
ere statistically significant risk factors for recurrent stroke/
IA. However, these results should be interpreted cau-
iously due to the large variance observed (confidence
ntervals 1.49 to 36.8 and 2.42 to 61.1, respectively).
hether PFO closure provides additional embolic protec-
ion for these patients beyond that conferred by warfarin
emains unclear. Conversely, whether the closure device
romotes thrombosis and emboli should be considered.
Elevations of right ventricular systolic and pulmonary
rtery pressures were also found to be significant predictors
f recurrent neurologic events. Reconciling this in a closed
FO is challenging. The pressures were only minimally
levated, making the clinical significance unclear. Addi-
ional studies should evaluate and attempt to corroborate
hese findings.
In summary, the questions that arise from this study are
rovocative and warrant further investigation. It is impera-
ive that, in the absence of randomized clinical data that
upport superiority or an approved indication for device
mplantation, cardiologists and neurologists continue to
ollaborate to define patients with the highest likelihood of
enefiting from PFO closure. The paper by Ford et al. (1)
akes us one step closer.
eprint requests and correspondence: Dr. Mark Reisman, Di-
ector, Cardiovascular Research, Swedish Heart and Vascular
nstitute, 550 17th Avenue, Suite 630, Seattle, Washington 98122.
-mail: mark.reisman@swedish.org.
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